Document |
Document Title |
WO/2024/083146A1 |
The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the...
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
WO/2024/065054A1 |
The application pertains to a biocide composition comprises an EDTA derivative of Formula (I) in which a hydrophobic moiety is covalently bound to the EDTA, and a photo sensitizer and/or a liquid carrier. Methods for inhibiting microbial...
|
WO/2023/213297A1 |
The present invention relates to a fused ring compound; specifically, provided in the present invention is the use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutical...
|
WO/2023/174378A1 |
The present invention relates to a nitrogen-containing heterocyclic compound. Specifically, provided in the present invention is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pha...
|
WO/2023/174381A1 |
The present invention relates to a nitrogen-containing heterocyclic compound and the use thereof. Specifically, provided is a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmace...
|
WO/2023/174377A1 |
The present invention relates to a tetracyclic compound and a use thereof. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer, a racemate, a solvate, a pharmaceutically acceptable salt, or...
|
WO/2023/169567A1 |
The present invention relates to an application of a tetracyclic compound in the treatment of tumors. Specifically provided is a use of a compound of formula I, an optical isomer or racemate thereof, a solvate thereof, a pharmaceutically...
|
WO/2023/138493A1 |
Disclosed are a crystal form of a high-stability nor-ursodeoxycholic berberine salt and a preparation method therefor, which relate to the field of pharmaceutical chemistry. The crystal form has the following structural formula. In X-ray...
|
WO/2023/088319A1 |
Disclosed is a montelukast berberine double salt or composition with anti-inflammatory, antibacterial and immunomodulatory effects. Particularly, disclosed are a montelukast berberine quaternary ammonium salt with a structure as represen...
|
WO/2023/027994A1 |
The present invention provides compositions and methods for treating nervous system disorders in a mammal. These compositions and methods comprise administering an effective amount of an antipurinergic agent according to a pharmacokineti...
|
WO/2023/015795A1 |
Disclosed are a ratiometric polysulfane fluorescent probe, and a preparation method therefor and the use thereof. The structural formula of the fluorescent probe is represented by formula (I). The fluorescent probe is obtained by reactin...
|
WO/2022/225108A1 |
The present invention relates to a composition for preventing or treating diseases caused by mitochondrial dysfunction, containing, as an active ingredient, an isoquinoline derivative compound represented by chemical formula 1, or a phar...
|
WO/2022/207699A1 |
The present invention pertains to enzyme-triggered self-reacting arm compounds, chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. The present invention...
|
WO/2022/194136A1 |
The invention belongs to the technical field of medicine. A soluble berberine-type quaternary ammonium alkaloid compound and the use thereof in preparing a drug are disclosed. In particular, disclosed are a compound as represented by gen...
|
WO/2022/166369A1 |
Disclosed is a crystal form A of a compound. The compound is S-(-)-2,3-methylenedioxy-5,8,13,13a-tetrahydro-10,11-dimetho
xy-6H- dibenzo[a,g]quinolizine, and the X-ray powder diffraction pattern of the crystal form A comprises three or m...
|
WO/2022/161468A1 |
The invention provides pharmaceutical compositions of berberine ursodeoxycholate (BUDCA) and methods of use thereof for the treatment primary sclerosing cholangitis, and related diseases and conditions.
|
WO/2022/120209A1 |
Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Compound I dihydrochloride. Also provided are processes of manufacture and methods of using the crystalline for...
|
WO/2022/099374A1 |
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
|
WO/2022/095972A1 |
The present invention relates to an application of an isoquinoline compound in tumor treatment. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer or a racemate thereof, or a solvate there...
|
WO/2022/057906A1 |
Disclosed are a compound for preventing and treating liver diseases and the pharmaceutical use thereof, which belong to the field of medical technology. Specifically disclosed is a compound as represented by formula I-1, or a pharmaceuti...
|
WO/2022/012693A1 |
The present invention relates to a codrug that disintegrates in the intestine, preparation therefor, and a use thereof. Specifically, provided is a codrug compound in formula I. Also provided are a method of using the present compound fo...
|
WO/2021/212691A1 |
A mitochondria targeting compound, a preparation method therefor and use thereof. The structure of the mitochondria targeting compound is as shown in formula I or formula II, wherein R1 and R2 are each independently selected from hydroge...
|
WO/2021/189112A1 |
A method for detection of a nerve agent in a sample, which method comprises (a) irradiating an optical sensing element, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, and measuring the lumi...
|
WO/2021/169658A1 |
Disclosed are a small molecule fluorescent probe and application thereof in chromosome analysis and cytogenetics. The present invention can be used as a multi-purpose tool for chromosome image segmentation to identify overlapping, cluste...
|
WO/2021/168561A1 |
The present invention provides solvent-limited processes for the preparation of an existing crystalline solid form of an active pharmaceutical ingredient comprising mixing, in the presence of solvent vapour, of a solid active pharmaceuti...
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
WO/2021/129720A1 |
Disclosed are a columbamine preparation method and a columbamine. The preparation method comprises: taking berberine hydrochloride, adding xylene and trichloroacetic acid to the berberine hydrochloride for reaction at a first predetermin...
|
WO/2021/129783A1 |
Disclosed are a preparation method for and an application of demethyleneberberine. The preparation method comprises the following steps: adding berberine hydrochloride to xylene, then adding trifluoromethanesulfonic acid, stirring at roo...
|
WO/2021/106975A1 |
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) (in the formula, each symbol is as described in the specification) or a salt thereof has orexi...
|
WO/2021/098737A1 |
The present invention falls within the medical field, and specifically relates to a fused heterocyclic derivative and a use thereof. The fused heterocyclic derivative has the structure of a compound as shown in formula (I), wherein the c...
|
WO/2021/067490A1 |
The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatoh...
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
WO/2021/050977A1 |
The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahyd
ro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of...
|
WO/2021/050473A1 |
The present disclosure relates to antimicrobial compositions, particularly to antibiotic compositions; to methods for identification of antimicrobial compositions involving in silico prediction of antimicrobial activity; and to use of an...
|
WO/2021/046194A1 |
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.
|
WO/2021/027792A1 |
The present invention relates to a class of compounds that serve as VMAT2 inhibitors, and relates in particular to a compound represented by formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, and a preparation me...
|
WO/2020/234272A1 |
The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10
,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car
boxylic acid with th...
|
WO/2020/234275A1 |
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...
|
WO/2020/234271A1 |
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10
,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car
boxylic acid with the fo...
|
WO/2020/234274A1 |
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...
|
WO/2020/221217A1 |
A fluorescent dye, a preparation method therefor, and a use thereof; the fluorescent dye is sensitive and specific to viscosity response, has the advantage of low background fluorescence, and can be used as a fluorescence activated dot l...
|
WO/2020/177744A1 |
Disclosed in the present invention are a salicylic acid berberine-type alkaloid quaternary ammonium compound as shown in general formula (I), a preparation method therefor, solubility characteristics, a pharmaceutical composition and an ...
|
WO/2020/143604A1 |
The present invention provides a dihydroisoquinoline compound or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug, or isotopic label thereof, having the structure of a compound of general formula I: (I). The c...
|
WO/2020/122092A1 |
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) [in the formula, each symbol is as described in the description] or a salt thereof has orexin ...
|
WO/2020/108330A1 |
The present disclosure relates to crystalline salt forms of the following Compound (1), also known as l-corydalmine or l-CDL, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in methods for the ...
|
WO/2019/196955A1 |
Disclosed are an 8-dihalide methyl berberine quaternary ammonium compound shown in formulas (I) and (II), a synthetic method therefor, and an application thereof in preparation of drugs. The 8-dihalide methyl berberine quaternary ammoniu...
|
WO/2019/174533A1 |
A small molecule PD-1/PD-L1 inhibitor and the use thereof in drugs. Specifically, provided is a small molecule PD-1/PD-L1 inhibitor that is a chemical compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, ox...
|
WO/2019/166962A1 |
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...
|
WO/2019/153644A1 |
Provided are four crystal forms, A, B, C and D, of demethylene berberine hydrochloride, and a preparation method therefor, and further provided are X‑ray powder diffraction characteristic absorption peaks, infrared absorption peaks and...
|